Owners and management
CVR: 44974045
Not available
Novo Holdings A/S (33,33-49,99%), Danmarks Eksport- og Investeringsfond (10-14,99%)
6 more
CVR · view owners
Martin Bonde
Board: Gabor Gyulveszi (chair) and 3 members
CVR · view management
Active
Founded 5 July 2024
CVR · view overview
No headcount reported
Owner registered: Novo Holdings A/S
CVR · 17/07/2026
View the full event history
Akylox Therapeutics ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2024. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Martin Bonde. The board consists of Gabor Gyulveszi (chair), Butrint Aliu, Martin Bonde and Pablo Gabriel Cironi Lopez. The company's owners include Novo Holdings A/S, Danmarks Eksport- og Investeringsfond and Alexander Thomas Hagen Flohr.
Selskabets formål er at forske, udvikle, producere, udnytte, erhverve, kommercialisere og/eller distribuere lægemidler og diagnostiske produkter og teknologier og aktiviteter relateret hermed efter direktionens skøn.
No annual financial figures are available for this company.
Screen owners and management against the Danish FSA's official PEP lists
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorThe CVR number of Akylox Therapeutics ApS is 44974045.
The owners of Akylox Therapeutics ApS include Novo Holdings A/S, Danmarks Eksport- og Investeringsfond and Alexander Thomas Hagen Flohr.
The management of Akylox Therapeutics ApS consists of Martin Bonde.
The board of Akylox Therapeutics ApS consists of Gabor Gyulveszi, Butrint Aliu and Martin Bonde, with Gabor Gyulveszi as chair.
Akylox Therapeutics ApS was founded on 5 July 2024.
Akylox Therapeutics ApS is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (industry code 721000).
Claim this page to add your logo and social links. Free to get started.
As of July 17, 2026, EY Godkendt Revisionspartnerselskab has been appointed auditor of Akylox Therapeutics ApS.
As of July 17, 2026, Martin Bonde has joined the board of directors of Akylox Therapeutics ApS.
As of July 17, 2026, Butrint Aliu has joined the board of directors of Akylox Therapeutics ApS.
As of July 17, 2026, Pablo Gabriel Cironi Lopez has joined the board of directors of Akylox Therapeutics ApS.
As of July 17, 2026, Maurits Jacob-Jan Brandt has left the board of directors of Akylox Therapeutics ApS.
As of July 17, 2026, Alexander Thomas Hagen Flohr has left the board of directors of Akylox Therapeutics ApS.
As of July 17, 2026, Matthias Paul Wymann has left the board of directors of Akylox Therapeutics ApS.
As of July 17, 2026, Novo Holdings A/S is registered as an owner of Akylox Therapeutics ApS with an ownership share of 33%.
As of July 17, 2026, Danmarks Eksport- og Investeringsfond is registered as an owner of Akylox Therapeutics ApS with an ownership share of 10%.
As of July 17, 2026, is registered as an owner of Akylox Therapeutics ApS with an ownership share of 5%.
As of July 17, 2026, is registered as an owner of Akylox Therapeutics ApS with an ownership share of 10%.
As of July 17, 2026, is registered as an owner of Akylox Therapeutics ApS with an ownership share of 5%.
As of July 17, 2026, is registered as an owner of Akylox Therapeutics ApS with an ownership share of 5%.
Akylox Therapeutics ApS has published its interim report for the period July 5, 2024 – December 31, 2025.
As of September 2, 2025, Gabor Gyulveszi has joined the board of directors of Akylox Therapeutics ApS.
As of September 2, 2025, Søren Sylvester Skjærbæk has left the board of directors of Akylox Therapeutics ApS.
As of May 13, 2025, is registered as an owner of Akylox Therapeutics ApS with an ownership share of 5%.
As of May 13, 2025, is registered as an owner of Akylox Therapeutics ApS with an ownership share of 5%.
As of January 31, 2025, Søren Sylvester Skjærbæk has joined the board of directors of Akylox Therapeutics ApS.
As of January 31, 2025, Morten Døssing has left the board of directors of Akylox Therapeutics ApS.
As of October 1, 2024, Martin Bonde is registered as adm. dir. of Akylox Therapeutics ApS.
As of September 30, 2024, Alexander Thomas Hagen Flohr has stepped down as director of Akylox Therapeutics ApS.
As of September 30, 2024, Sebastian Kim Lugert has stepped down as director of Akylox Therapeutics ApS.
As of September 24, 2024, Morten Døssing has joined the board of directors of Akylox Therapeutics ApS.
As of September 24, 2024, Maurits Jacob-Jan Brandt has joined the board of directors of Akylox Therapeutics ApS.
As of September 24, 2024, Alexander Thomas Hagen Flohr has joined the board of directors of Akylox Therapeutics ApS.
As of September 24, 2024, Matthias Paul Wymann has joined the board of directors of Akylox Therapeutics ApS.
As of July 5, 2024, Alexander Thomas Hagen Flohr is registered as director of Akylox Therapeutics ApS.
As of July 5, 2024, Sebastian Kim Lugert is registered as director of Akylox Therapeutics ApS.
Akylox Therapeutics ApS was founded on July 5, 2024.
Companies in the same industry and area
CVR 40766383
CVR 42597333
CVR 46613139
CVR 44504332
CVR 43917897
